KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Cash from Financing Activities (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Cash from Financing Activities for 18 consecutive years, with $57.3 million as the latest value for Q1 2026.

  • For Q1 2026, Cash from Financing Activities rose 2503.82% year-over-year to $57.3 million; the TTM value through Mar 2026 reached $730.9 million, up 60.04%, while the annual FY2025 figure was $675.8 million, 41.37% up from the prior year.
  • Cash from Financing Activities hit $57.3 million in Q1 2026 for Ionis Pharmaceuticals, down from $591.2 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $591.2 million in Q4 2025 and bottomed at -$51.0 million in Q4 2022.
  • Average Cash from Financing Activities over 5 years is $105.9 million, with a median of $2.6 million recorded in 2024.
  • On a YoY basis, Cash from Financing Activities climbed as much as 11713.83% in 2023 and fell as far as 1859.38% in 2023.
  • Ionis Pharmaceuticals' Cash from Financing Activities stood at -$51.0 million in 2022, then skyrocketed by 179.82% to $40.7 million in 2023, then tumbled by 208.33% to -$44.1 million in 2024, then soared by 1440.05% to $591.2 million in 2025, then plummeted by 90.31% to $57.3 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $57.3 million, $591.2 million, and $81.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.